Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic release_4s7n4rxppvbwlgtttpwoytxw24

by Caitlin R Hopkins, Joseph A Fraietta

Published in European medical journal by European Medical Group.

2021  

Abstract

Chimeric antigen receptor (CAR) T cells have emerged as an effective therapy for patients with relapsed and refractory haematological malignancies. However, there are many challenges preventing clinical efficacy and thus broader translation of this approach. These hurdles include poor autologous T cell fitness, manufacturing issues and lack of conserved tumour-restricted antigens to target. Recent efforts have been directed toward incorporating genome editing technologies to address these challenges and develop potent CAR T cell therapies for a diverse array of haematopoietic cancers. In this review, the authors discuss gene editing strategies that have been employed to augment CAR T cell fitness, generate allogeneic 'off-the-shelf' CAR T cell products, and safely target elusive myeloid and T cell cancers that often lack appropriate tumour-specific antigens.
In application/xml+jats format

Archived Files and Locations

application/pdf   721.7 kB
file_b3wa4yjpibb37pfqvurgmigdci
emj.emg-health.com (web)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2021-12-13
Container Metadata
Open Access Publication
In DOAJ
In ISSN ROAD
Not in Keepers Registry
ISSN-L:  2397-6764
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 622d59ea-ff78-47bb-8159-b37f83e9bb77
API URL: JSON